Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SHR-8068 injection in combination with antitumor therapy in colorectal cancer
CTR20252709Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002 in colorectal adenocarcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jul 2025; status: active.
02
Drugs
CS1002
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20252709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252709.